Technical guidelines for Integrated Disease Surveillance and Response in Kenya (2012). Ministry of Public Health and Sanitation. Pg 315-317
Mukhtar MM, Sharief AH, El Saffi SH, Harith AE, Higazzi TB, Adam AM, Abdalla HS. Detection of antibodies to Leishmania donovani in animals in a kala-azar endemic region in eastern Sudan: a preliminary report. Trans R Soc Trop Med Hyg 2000; 94(1):33–36. doi.org/10.1016/S0035-9203(00)90429-2.
Kenubih A, Dagnachew S, Almaw G, Abebe T, Takele Y, Hailu A, Lemma W. Preliminary survey of domestic animal visceral leishmaniasis and risk factors in north-west Ethiopia. Trop Med Int Health 2015;20(2):205-10. doi: 10.1111/tmi.12418.
Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671.
Chappuis F, Mueller Y, Nguimfack A, Rwakimari JB, Couffignal S, Boelaert M, Cavailler P, Loutan L, Piola P. Diagnostic accuracy of two rK39 antigen-based dipsticks and the Formol Gel test for the rapid diagnosis of visceral leishmaniasis in north-eastern Uganda. J Clin Microbiol 2005; 43(12): 5973-7. doi: 10.1128/JCM.43.12.5973-5977.2005
Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, O'keeffe C, Davidson RN. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg. 2006; 74(1): 76-80.
Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW. Rapid, non-invasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-k39 antibody. J Clin Microbiol 2006; 44(1): 251-3.
Reithinger R, Brooker S, Kolaczinski JH. Visceral leishmaniasis in eastern Africa–current status. Trans R Soc Trop Med Hyg 2007; 101: 1169-1170.
Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006; 43: 357–364.
Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 2003; 97: 597–598.
Musa A, Khalil E, Hailu A, Olobo J,Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E,Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M. Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial. PLoS Negl Trop Dis 2012; 6: e1674. doi:10.1371/journal.pntd.0001674
Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007; 77:89–94.
Shiferaw Y, Wondimeneh Y, Wondifraw H, Ferede G. Trend Analysis of Visceral Leishmaniasis in Metema Hospital Northwest, Ethiopia. J Epidemiol Public Health Rev 2016; 1(5): doi http://dx.doi.org/10.16966/2471-8211.129
Mueller YK, Kolaczinski JH, Koech T, Lokwang P, Riongoita M, Velilla E, Brooker SJ, Chappuis F. Clinical Epidemiology, Diagnosis and Treatment of Visceral Leishmaniasis in the Pokot Endemic Area of Uganda and Kenya. Am J Trop Med Hyg 2014; 90 (1): 33-39. DOI: 10.4269/ajtmh.13-0150
Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrob Agents Chemother 2015; 59 (1): 1-14. doi: 10.1128/AAC.04298-14.
Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg 2001; 95 Suppl 1: S27–S58.